Active, not recruitingPhase 2NCT04585893
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
Studying TAFRO syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Principal Investigator
- Matthew Painschab, MDUniversity of North Carolina
- Intervention
- Rituximab(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- UNC Project, Kamuzu Central Hospital, Lilongwe, Malawi
Collaborators
Fogarty International Center of the National Institute of Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04585893 on ClinicalTrials.gov